List view / Grid view
Biological products, usually referred to as biologics, constitute a significant segment of pharmaceuticals in development. Biologics include therapeutic proteins, antibody drugs, antibody-drug conjugates (ADCs), vaccines, carbohydrates drugs, blood and tissue-derived pharmaceuticals, gene therapies, even live cells and tissues...
Read the free-to-view digital version of the latest issue of European Pharmaceutical Review...
In this Mass Spectrometry In-Depth Focus: Mass spectrometry in the development of protein biologics; and GC-MS applications in pharmaceuticals analysis...
Thermo Fisher Scientific Inc., the world leader in serving science, announced a line-up of new products at the 2017 Pittcon Conference and Exhibition that enable application-specific workflows for pharma/biopharma, materials science, and environmental and food safety markets.
Newest spectrometer from Ocean Optics offers Ethernet operation, speed, sensitivity and spectral buffering...
21 February 2017 | By Syft Technologies
SIFT-MS is a new tool for real-time, selective and economical trace gas and headspace analysis. SIFT-MS uses soft chemical ionisation to quantify volatile compounds, including chromatographically challenging ones such as formaldehyde, formic acid, and ammonia...
In this issue: Regulation, Environmental Monitoring, Drug Delivery; Microbiology, Track & race, Spectroscopy, HPLC, Mass Spectrometry, and much more...
As a technology, mass spectrometry (MS) has evolved to the point where it is used throughout the drug development process. In particular, when MS is coupled with high-performance liquid chromatography (HPLC) it adds an orthogonal detection function for sample analysis and provides unique capabilities for pharmaceutical analysis, such as sensitivity,…
Since the 1970s, the advent of biotechnology has resulted in the development and commercialisation of many therapeutic proteins, including antibodies and antibody fragments, for the treatment of human diseases. Examples include antibody treatments for autoimmune diseases (for example, adalimumab [Humira®] for rheumatoid arthritis), cancers (such as trastuzumab [Herceptin®] for breast…
This whitepaper focuses on developing biochemical assays where substrate and product are small molecules using a novel MALDI-HTS system...
In this issue: Regulation, Oncology, Single Use, Robotics, Microbiology, PAT, Mass Spectrometry, Drug Delivery, Nanotechnology, and much more...
In this Mass Spectrometry In-Depth Focus: Novel trends in glycosylation analysis of biotherapeutics by mass spectrometry; The use of mass spectrometry for the characterisation of proteins in small molecule drug discovery; Mass Spectrometry Q&A...
28 April 2016 | By Bruker Biospin
Dr Matthias Trost, Programme Leader & Head of Proteomics for the MRC Protein Phosphorylation and Ubiquitylation Unit at University of Dundee, presents his recent work using MALDI TOF mass spectrometry in the ubiquitin system...
26 April 2016 | By Victoria White, Digital Content Producer
In an exclusive interview, Erin Seeley of Protea Biosciences discusses Proteomic Mass Spectrometry Imaging and Protea's recently announced license agreement with Yale...
MALDI-ToF mass spectrometry, a phenotypical RMM for microbial identification, is a unique, highly accurate alternative method that facilitates cost-effective, precise and rapid data acquisition.
